Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Advanced Breast Cancer × pyrotinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 54 HER2-positive Breast Cancer 15 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 4 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Advanced Breast Cancer 3 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

Vinorelbine 3 Capecitabine 2 ribociclib 1 pyrotinib 1 Trastuzumab 1 Lapatinib 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05856383 2023-05-12

HER2-VIP

Zhejiang Cancer Hospital

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡